PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
48.96%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.88%
Less SBC growth vs. AXSM's 5.59%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-128.88%
Negative yoy working capital usage while AXSM is 0.00%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-244.33%
Both negative yoy AP, with AXSM at -56.31%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
1043.06%
Growth well above AXSM's 100.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-114.48%
Both negative yoy, with AXSM at -19.79%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-59.54%
Negative yoy CFO while AXSM is 25.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.03%
We repay more while AXSM is negative at -29.18%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.